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ABSTRACT
Objectives  To assess the effect of a temporary 
interruption in subcutaneous (SC) abatacept on 
immunogenicity, safety and efﬁ  cacy in patients with 
active rheumatoid arthritis despite methotrexate in a 
phase III trial.
Methods  Following a 12-week open-label introduction 
(period I; intravenous abatacept loading dose and 
weekly ﬁ  xed-dose SC abatacept 125 mg), patients 
were randomised 2:1 to double-blind SC placebo or SC 
abatacept for 12 weeks (period II). At the end of period II, 
patients receiving SC abatacept continued treatment and 
patients on placebo were reintroduced to SC abatacept 
(12-week open-label period III). The co-primary end points 
were ELISA-detected immunogenicity rate and safety at 
the end of period II. Efﬁ  cacy was also monitored.
Results  Of 167 patients entering period I, 72% qualiﬁ  ed 
for period II; during periods II and III, three patients 
discontinued treatment. Mean (SD) disease duration 
was 6.6 (6.5) years and Disease Activity Score 28 was 
4.8 (0.8). The primary end point was met, with a non-
signiﬁ  cant increase in immunogenicity upon withdrawal 
(7/73 placebo vs 0/38 abatacept in period II; p=0.119) 
which was reversed upon reintroduction of SC abatacept 
(2/73 vs 1/38, end period III). Safety was comparable 
regardless of withdrawal, with no unexpected events 
upon reintroduction. Two patients experienced reactions 
at the SC injection site. On withdrawal, patients 
experienced slight worsening in efﬁ  cacy which improved 
following reintroduction.
Conclusions  Overall immunogenicity to SC abatacept 
is low, consistent with intravenous abatacept, and is 
not signiﬁ  cantly affected by a 3-month interruption and 
reintroduction. This stop–start schedule was well tolerated, 
with little impact on safety and efﬁ  cacy. These are important 
considerations for the clinical use of SC abatacept.
ClinicalTrials  gov Identiﬁ  er NCT00533897
INTRODUCTION
Patients with rheumatoid arthritis (RA) receive long-
term treatment and sometimes require interruption 
of therapy—for example, in the event of surgery or 
side effects. Such interruption in biological disease-
modifying antirheumatic drugs (DMARDs) may 
lead to reduced drug concentration which may 
heighten the potential for drug-induced antibody 
responses.1 2 Immunogenicity can, in turn, reduce 
drug concentrations via antibody-mediated drug 
clearance, and reduce efﬁ  cacy by preventing drug 
binding to the target. In addition, general immune-
mediated toxicities such as infusion and subcuta-
neous (SC) injection site reactions may increase.1–3 
This has been seen with the anti-tumour necrosis 
factor agent inﬂ  iximab, for which serum sickness-
like reactions have been observed at initiation and 
at reintroduction following extended withdrawal; 
such reactions were associated with increased 
immunogenicity, reduced serum concentrations 
and potential loss of efﬁ  cacy.4–7
Experience with intravenous abatacept has dem-
onstrated consistent safety and sustained efﬁ  cacy, 
and a low immunogenicity rate that has no signiﬁ  -
cant impact on pharmacokinetics, safety and efﬁ  ca-
cy.1 Theoretically, administration of abatacept via 
the SC route may have an increased risk for immu-
nogenicity due to potential differences in antigen 
presentation.2 8 Fixed (125 mg/week) dosing of SC 
abatacept has so far demonstrated low immunoge-
nicity rates and titres, and comparable drug expo-
sure to intravenous abatacept.9 SC administration 
of abatacept is generally safe and well tolerated in 
patients with RA, with comparable efﬁ  cacy to that 
seen with intravenous administration.9–11
This study assessed the effect of temporary 
withdrawal and reintroduction of 125 mg/week SC 
abatacept on immunogenicity, safety and efﬁ  cacy 
in patients with RA.
METHODS
Patients
Patients in the ALLOW (Evaluation of Abatacept 
Administered SubcutaneousLy in AduLts With 
Active RheumatOid Arthritis: Impact of Withdrawal 
and Reintroduction on Immunogenicity, Efﬁ  cacy 
and Safety) trial met the criteria of the American 
Rheumatism Association (1987) for RA diagnosis 
and the American College of Rheumatology (1991) 
functional classes I, II or III. Patients had to have a 
Disease Activity Score 28 (DAS28; C reactive pro-
tein (CRP)) of 3.2–5.1 and received methotrexate 
(MTX) for ≥3 months prior to treatment.
Patients were excluded if they had serious acute 
or severe chronic/recurrent bacterial infection, or evi-
dence of latent bacterial or viral infection, or were pre-
viously treated with rituximab, abatacept, live vaccine 
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Period III (Reintroduction) was an OL 12-week period end-
ing on day 253. To enter period III, patients had to have been 
treated in (but not necessarily completed) period II. In all patients 
regardless of randomisation group, OL SC abatacept 125 mg was 
self-administered weekly throughout period III. Patients who 
received SC placebo during period II were randomised (1:1) to 
receive either an intravenous placebo or intravenous abatacept 
loading dose (approximately 30 min before SC abatacept dosing 
at the beginning of period III (day 169)) to determine whether 
the administration of the intravenous abatacept loading dose 
affected immunogenicity upon reintroduction. Patients ran-
domised to SC abatacept during period II received intravenous 
placebo loading on day 169 to maintain blinding.
A 4-week washout period was required for azathioprine, 
gold, etanercept or anakinra and an 8-week washout period was 
required for adalimumab or inﬂ  iximab. Patients receiving sul-
fasalazine, chloroquine or hydroxychloroquine had to discon-
tinue at screening.
Throughout the trial, low-dose (≤10 mg/day prednisone 
equivalent) oral corticosteroids were permitted but had to be 
stable for 25 of the 28 days before entry. Additionally, up to 
two high-dose corticosteroid courses were permitted during 
period II and one course during periods I and III (excluding 28 
days before disease activity assessment at day 78 in period I). 
Biological and DMARD therapies other than MTX were not 
permitted. The MTX dose had to be stable (at least 10 mg/
week) prior to study entry; increases in MTX dose were not 
permitted during the study, although decreases were allowed 
for toxicity.
Immunogenicity assessments
Blood samples were collected prior to intravenous infusions 
on days 1 and 169 and prior to SC injections on days 57, 78, 
85, 113, 141, 197, 225 and 253. For the primary measure of 
(≤3 months of ﬁ  rst study dose or planned during study), leﬂ  unomide 
(≤1 year of screening) or any non-approved investigational biologi-
cal agent.
Trial design
This multinational study consisted of three periods followed by 
a long-term extension (LTE) (ﬁ  gure 1). The study was conducted 
in accordance with the Declaration of Helsinki and was consis-
tent with International Conference on Harmonization of Good 
Clinical Practice.12
Period I (Introduction) was an open-label (OL) 12-week 
period ending on day 85. On day 1, patients received a single 
intravenous dose of abatacept (~10 mg/kg based on weight 
range; the ‘loading dose’), followed 30 min later by SC abata-
cept 125 mg. The single intravenous loading dose was given to 
ensure target therapeutic trough concentrations were achieved 
as quickly as possible. Thereafter, SC abatacept 125 mg was 
delivered at weekly intervals for the remainder of the 12-week 
period. Disease activity was assessed at day 78. Patients who 
had achieved an improvement in DAS28 (reduction of ≥0.6 from 
baseline; one times the measurement error and statistically con-
sidered a change) were randomised into period II; patients with 
DAS28 reduction <0.6 could directly enter the LTE.
Period II (Withdrawal) was a 12-week double-blind, placebo-
controlled period ending on day 169, in which patients were 
randomised 2:1 to SC placebo or SC abatacept 125 mg/week. 
Patients could prematurely enter period III if RA symptoms per-
sisted or worsened after symptomatic treatment in this period. 
This 12-week withdrawal period was determined to be sufﬁ  -
cient for assessing development of immunogenicity because, at 
this time, serum concentrations of abatacept would be too low 
to interfere with the assay, and any immunosuppressive effect 
of abatacept that may interfere with immunogenicity would 
have ceased.
Figure 1  Study design. *Most frequent reason for not being treated was no longer meeting entry criteria. †Patients who discontinued during period 
II (Withdrawal phase) due to lack of efﬁ  cacy could enter period III (Reintroduction phase) prematurely. IV, intravenous; LTE, long-term extension; MTX, 
methotrexate; SC, subcutaneous.Clinical and epidemiological research
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were evaluated at each visit. The proportions of patients achiev-
ing low disease activity state (LDAS; DAS28 ≤3.2) and DAS28-
deﬁ  ned remission (DAS28 <2.6) were determined.
Statistical methods
The sample size of 105 patients, allocated 2:1 to receive SC 
placebo and SC abatacept during period II, was calculated to 
yield approximately 90% power to detect an absolute differ-
ence of 30% in the immunogenicity rate between period II 
treatment groups at the 5% signiﬁ  cance level; this assumes 
an immunogenicity rate of 5% with SC abatacept at the end 
of period II and an overall discontinuation rate of 5% during 
period II.
Immunogenicity was analysed for patients with serum sam-
ples available at the visits of interest (as-observed) in period I 
(all patients treated during period I), period II (all patients ran-
domised and treated in period II) and period III (all patients 
treated in period II and subsequently treated in period III). 
Immunogenicity rates are summarised over time using point 
estimates and within-group 95% CI, with 95% CI for between-
group differences calculated at days 169 and 253. A continuity 
corrected χ2 test was used to compare the immunogenicity rate 
between groups on day 169 (p value evaluated at the 0.05 sig-
niﬁ  cance level).
Safety is reported for each period for all patients who received 
≥1 dose of study drug during that period. Efﬁ  cacy results are pre-
sented for patients treated in period II who had data available at 
the visit of interest (as-observed).
immunogenicity, two validated ELISAs (Prevalere Life Sciences 
Inc., Whitesboro, NY, USA) were used; one determined the pres-
ence of antibodies to whole molecule abatacept (including both 
the CTLA4 and IgG portions) and one detected the presence of 
antibodies to the CTLA4 ‘tip’ portion alone (CTLA4-T). The 
primary end point of the study was the immunogenicity rate, 
expressed as the proportion of patients with an immunogenic 
response (ELISA) on day 169. In addition to ELISA, an electro-
chemiluminescence (ECL) immunoassay (Meso-Scale Discovery, 
Gaithersburg, Maryland, USA), which is more sensitive than 
ELISA, was used as a secondary assay and evaluated through-
out. ELISA and ECL samples found positive in screening were 
veriﬁ  ed by a second conﬁ  rmatory assay and titre determination. 
Pharmacokinetic assessments were also made in this study and 
will be presented in a separate report.
Safety assessments
Adverse events (AEs) and serious adverse events (SAEs) were 
classiﬁ  ed using the Medical Dictionary for Regulatory Activities 
(Version 12.1). Injection and infusion reactions were pre-speciﬁ  ed 
and classiﬁ  ed as SC injection site reactions (AEs at the site of SC 
injection) and acute infusion AEs (occurring within 1 h of the start 
of intravenous infusion). Autoimmune events were pre-speciﬁ  ed 
based on the potential association with biological treatment.
Efﬁ  cacy assessments
Efﬁ  cacy assessments were secondary objectives; DAS28 and the 
Health Assessment Questionnaire-Disability Index (HAQ-DI) 
Figure 2  Patient disposition. *Most frequent reason for not being treated was no longer meeting entry criteria. †Patients discontinued period II 
(Withdrawal phase) early due to disease ﬂ  are and directly entered period III (Reintroduction phase). IV, intravenous; LTE, long-term extension; SC, 
subcutaneous.Clinical and epidemiological research
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respectively (estimate of difference 9.59 (95% CI 0.83 to 18.34), 
p=0.119; table 2). Of the 7/73 patients with a positive response 
in the SC placebo group at the end of period II, one patient was 
positive for anti-abatacept antibodies and six for anti-CTLA4-T 
antibodies.
Period III (Reintroduction)
Of the seven patients who were positive for antibodies at the end 
of period II, three patients remained positive after drug reintro-
duction; one was negative by the end of period III, one (period II 
SC placebo group) had persistent antibodies throughout period 
III and one had persistent positivity at all post-treatment assess-
ments following discontinuation. At the last visit of period III 
(day 253), 1/38 patients treated with SC abatacept during period 
II and 2/73 patients treated with SC placebo during period II had 
positive responses (table 2). For two of these patients (one from 
each period II treatment group), antibodies were detected only 
at this assessment.
Immunogenicity following reintroduction of SC abatacept 
for patients randomised to SC placebo in period II was simi-
lar regardless of whether they received intravenous abatacept 
or intravenous placebo loading at the start of the reintroduc-
tion period (0/32 and 2/41 (both anti-CTLA4-T), respectively, 
at day 253; estimate of difference 4.88% (95% CI –4.50% to 
14.25%)).
Immunogenicity by ECL
Immunogenicity assessed by this secondary assay was consis-
tent with the ELISA observations (data not shown).
Safety
Overall, 49.1% of patients experienced an AE during period I. 
The frequency of AEs remained consistent during periods II and 
III and was similar between groups (table 3). The majority of 
AEs were mild or moderate. Throughout the study, SAEs were 
reported in six patients: three in period I (cholelithiasis, extreme 
fatigue, cellulitis and pulmonary embolism), two in period II 
(osteoarthritis of the right hip, and rectal ﬁ  ssure, laceration, pel-
vic fracture (motorcycle accident)) and one in period III (severe 
back pain, urinary retention and benign prostatic hypertrophy). 
The patient with pulmonary embolism died as a result of the 
event; all other SAEs resolved.
The frequency of infection was similar between groups in 
periods II and III (table 3). The most common infections (occur-
ring in ≥5% of patients) were vaginal infection during period 
II and urinary tract infection, upper respiratory tract infection, 
laryngitis and ﬂ  u during period III. Only two infections were 
severe (cellulitis and gastroenteritis salmonella), both of which 
occurred in period I. The cellulitis event was considered a seri-
ous infection and led to discontinuation.
Reactions at the SC injection site were rare and mild (table 3), 
with only two events reported (haematoma and pruritus in 
period I); no injection site reactions were reported upon drug 
reintroduction. Four patients (2.4%) in period I experienced 
hypertension of mild or moderate intensity within 24 hours of 
SC injection. One further moderate case was reported in period 
II in a patient withdrawn from SC abatacept. No anaphylactic 
reactions were reported.
Clinical efﬁ  cacy
For patients treated in period II, mean (SD) DAS28 at baseline 
(day 1) was 4.80 (0.83). At the end of period I signiﬁ  cant reduc-
tions from baseline in DAS28 were observed (ﬁ  gure 3A). For 
patients who continued to receive SC abatacept throughout 
RESULTS
Patient disposition and baseline demographics
A total of 157/167 patients (94.0%) completed period I 
(Introduction); 120 (71.9%) qualiﬁ  ed for period II (ﬁ  gure 2). In 
period II (Withdrawal), 40 and 80 patients were treated with SC 
abatacept and SC placebo, respectively. Forty and 79 patients 
entered period III (Reintroduction), with 40 and 77 completing 
period III.
For patients who were treated during period II, baseline dis-
ease characteristics were consistent with mild-to-moderate 
active inﬂ  ammatory disease and were similar between treat-
ment groups (table 1). All patients had received prior MTX treat-
ment and >90% had not received biological agents.
In period I, 49.7% of patients received corticosteroids (oral 
and/or injectable); the mean (SD) oral dose was 3.1 (3.8) mg. 
Five patients (3.0%) received symptomatic treatment with 
high-dose corticosteroids in period I (oral (≥40 mg/day), 
intramuscular or intravenous). In period II, 57.5% of patients 
treated with SC abatacept and 55.0% of those given SC pla-
cebo received corticosteroids (mean (SD) oral doses 4.2 (5.0) 
vs 3.8 (4.6) mg). One patient (1.3%) in the SC placebo group 
received high-dose corticosteroids. During period III, 55.0% of 
patients treated with SC abatacept and 54.4% of those given 
SC placebo received corticosteroids (mean (SD) oral doses 3.6 
(4.4) vs 3.4 (4.1) mg). One patient (2.5%) in the SC abatacept 
group received high-dose corticosteroids. During the course of 
the trial no patient received high-dose corticosteroids for ≥28 
days.
Immunogenicity
End of period II (Withdrawal)
The immunogenicity rate (ELISA) at the end of period II (day 
169) was low with a positive response in 0% (0/38) and 9.6% 
(7/73) of patients in the SC abatacept and SC placebo groups, 
Table 1  Demographic and clinical characteristics at baseline* for 
patients treated in period II (Withdrawal phase)
  SC abatacept (n=40) SC placebo (n=80)
Age (years) 48.9 (14.2) 49.1 (12.8)
Weight (kg) 67.9 (15.8) 68.9 (14.7)
Weight category, n (%)
  <60 kg 14 (35.0) 19 (23.8)
  60–100 kg 25 (62.5) 60 (75.0)
  >100 kg   1 (2.5)   1 (1.3)
Gender (% female) 85.0 83.8
Race (% Caucasian) 95.0 93.8
Disease duration (years) 7.4 (7.7) 6.2 (5.8)
Tender joints 13.6 (7.7) 14.6 (9.2)
Swollen joints 10.5 (5.4) 10.6 (5.4)
Disease activity, DAS28 (CRP) 4.8 (0.8) 4.8 (0.8)
HAQ-DI 1.4 (0.7) 1.3 (0.7)
RF positive (%) 85.0 86.1
CRP level (mg/dl) 1.27 (1.76) 1.23 (1.54)
Prior antirheumatic drug, n (%)
  Systemic corticosteroids 24 (60) 41 (51.3)
  Methotrexate 40 (100) 80 (100)
  Cyclophosphamide  0  (0)  1  (1.3)
  Leﬂ   unomide  0  (0)  2  (2.5)
  Etanercept  1  (2.5)  2  (2.5)
  Inﬂ   iximab  0  (0)  4  (5.0)
 Adalimumab  2  (5.0)  2  (2.5)
Data are mean (SD) unless otherwise stated.
*Baseline is the start of period I.
CRP, C reactive protein; DAS28, Disease Activity Score 28; HAQ-DI, Health Assessment 
Questionnaire-Disability Index; RF, rheumatoid factor; SC, subcutaneous.Clinical and epidemiological research
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Impact of immunogenicity on efﬁ  cacy and safety
Based on the seven patients treated with SC placebo who were 
seropositive (ELISA) at the end of period II, the presence of 
antibodies did not affect the safety or efﬁ  cacy of SC abatacept. 
Following reintroduction, all but one of these patients demon-
strated an efﬁ  cacy response at the end of period III based on 
DAS28 and/or HAQ-DI. None of these seven patients experi-
enced SAEs or severe or drug-related AEs after reintroduction, 
whether SC abatacept was reintroduced with or without intra-
venous abatacept loading.
DISCUSSION
In clinical practice, patients may experience periods when treat-
ment is temporarily withdrawn and reintroduced. Given the risk 
of increased immunogenicity and the potential impact on safety 
and efﬁ  cacy resulting from treatment withdrawal and reintro-
duction, evaluating these outcomes is important.
The present study showed that, following a response to SC 
abatacept, 3-month interruption followed by reintroduction 
period II (withdrawal), mean reductions were sustained 
throughout period II and remained stable during period III 
(ﬁ  gure 3A). For patients who had SC abatacept withdrawn in 
period II, DAS28 worsened slightly during withdrawal (ﬁ  gure 
3A) and improved following reintroduction of SC abatacept 
and, by the end of period III (day 253), was comparable to 
patients maintained on SC abatacept (ﬁ  gure 3A). Mean DAS28 
scores by the end of period III were similar, irrespective of 
whether or not patients received intravenous abatacept load-
ing at reintroduction. High proportions of patients achieved 
DAS28-deﬁ  ned LDAS and remission by the end of period III, 
regardless of whether they were withdrawn from SC abatacept 
(ﬁ  gure 3B).
Patients treated during period II had a mean (SD) HAQ-DI 
of 1.30 (0.66) at baseline. For patients maintained on SC abata-
cept during period II, mean reductions from baseline seen in 
period I were maintained through periods II and III (ﬁ  gure 3C). 
For patients withdrawn from SC abatacept, mean reductions in 
HAQ-DI seen in period I deteriorated slightly following with-
drawal and improved upon reintroduction.
Table 2 Immunogenicity  summary
 
End of period II (Withdrawal phase) End of period III (Reintroduction phase)*
Period II SC 
abatacept (n=40)
Period II SC 
placebo (n=80)
Period II SC abatacept† 
(n=40)
Period II SC 
placebo‡ (n=79)
Anti-abatacept, n/N (%) 0/37 (0) 1/71 (1.4) 0/38 (0) 0/73 (0)
95% CI – 0.0 to 4.1 – –
Anti-CTLA4-T, n/N (%) 0/38 (0) 6/73 (8.2) 1/38 (2.6) 2/73 (2.7)
95% CI – 1.9 to 14.5 0.0 to 7.7 0.0 to 6.5
Total, n/N (%) 0/38 (0) 7/73 (9.6) 1/38 (2.6) 2/73 (2.7)
95% CI – 2.8 to 16.3 0.0 to 7.7 0.0 to 6.5
Estimate of difference, % (95% CI) 9.59 (0.83 to 18.34) 0.11 (–8.21 to 8.43)
p Value 0.119 –
*All patients received SC abatacept during period III, with results shown by period II treatment group.
†Patients received intravenous placebo loading at the start of period III.
‡Patients received intravenous abatacept or intravenous placebo (1:1 ratio) loading at the start of period III.
SC, subcutaneous.
Table 3 Safety  summary
Patients with event (n (%))
Period I 
(Introduction phase)
Period II 
(Withdrawal phase)
Period III 
(Reintroduction phase)
SC abatacept 
(with intravenous 
abatacept load) 
(n=167)
SC abatacept 
(n=40)
SC placebo 
(n=80)
Period II SC abatacept 
(with intravenous 
placebo load) (n=40)
Period II SC placebo
Intravenous 
abatacept load 
(n=35)
Intravenous placebo 
load (n=44)
AEs 82 (49.1) 13 (32.5) 29 (36.3) 15 (37.5) 17 (48.6) 16 (36.4)
Most common AEs*
  URTI 12  (7.2)  1  (2.5)  0  2  (5.0)  1  (2.9)  1  (2.3)
  Vaginal  infection  0  2  (5.0)  0  0  0  0
  Nausea  2  (1.2)  2  (5.0)  0  0  0  0
  Flu  5  (3.0)  0  1  (1.3)  0  2  (5.7)  2  (4.5)
  UTI  3  (1.8)  1  (2.5)  1  (1.3)  3  (7.5)  0  1  (2.3)
  Laryngitis  1  (0.6)  0  0  0  3  (8.6)  0
Discontinuations  due  to  AEs  1  (0.6)  0  0  0  0  0
SAEs  3  (1.8)  0  2  (2.5)  0  0  1  (2.3)
Deaths  1  (0.6)  0  0  0  0  0
Infections and infestations 42 (25.1)   5 (12.5)   7 (8.8)   7 (17.5)   8 (22.9)   7 (15.9)
  Serious  infections†  1  (0.6)  0  0  0  0  0
Malignancies  0  0  0  0  0  0
Autoimmune  events  0  0  0  0  0  0
SC  injection  site  reaction  2  (1.2)  0  0  0  0  0
Acute infusional events  1  (0.6)‡  0  0  0  0  0
*AEs reported in ≥5% of patients in any group during any treatment period.
†Serious infections is a subset of SAEs.
‡Mild non-serious headache, considered probably related to study drug, was reported following intravenous abatacept loading in period I.
AE, adverse event; SAE, serious adverse event; SC, subcutaneous; URTI, upper respiratory tract infection; UTI, urinary tract infection.Clinical and epidemiological research
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kept on treatment. After reintroduction of abatacept, <3% of 
patients demonstrated immunogenicity with only one case of 
persistent seropositivity. Immunogenicity was low regardless 
of whether intravenous abatacept or intravenous placebo was 
administered at reintroduction. Immunogenicity also appeared 
to have little effect on safety and efﬁ  cacy, as shown in patients 
in whom treatment was withdrawn and subsequently reintro-
duced. Importantly, these data also demonstrate that immu-
nogenicity with SC abatacept is consistent with intravenous 
administration.1 11
The low immunogenicity rates observed with SC abatacept 
mirror those observed in other SC abatacept studies. In a phase 
II study9 assessing weight-tiered versus ﬁ  xed SC dosing over 4 
months, only one of 51 patients demonstrated immunogenicity. 
This was transient and the patient was seronegative at study 
completion. Results from subsequent phase III studies have dem-
onstrated low rates of immunogenicity. In a 4-month OL phase 
III study of SC abatacept with or without MTX, only four cases 
of transient immunogenicity were observed.10 Immunogenicity 
observed with SC abatacept9 10 is at the lower end of that seen 
with other biological agents. Immunogenicity rates of between 
17% (21 patients) and 20% (46 patients) over 28 weeks have 
been seen with SC adalimumab,13 14 immunogenicity rates 
of approximately 6% (12 patients) over 24 weeks have been 
reported with SC etanercept15 and rates of 44% (33 patients) 
over 24 weeks have been found with intravenous inﬂ  iximab.6
The safety of SC abatacept was consistent across periods dur-
ing this study. Importantly, in patients in whom SC abatacept 
was withdrawn and reintroduced, the frequency of AEs did not 
increase and no unexpected events occurred compared with those 
who received continuous treatment. The incidence of infection 
with SC abatacept was consistent with intravenous administra-
tion, with the majority of events mild or   moderate.16 17 There 
were no reports of autoimmune events or malignancies. The inci-
dence of injection site reactions was low and all events were mild-
to-moderate in intensity. Previous studies with SC abatacept have 
also reported a low incidence of injection site reactions,18 with 
fewer events seen with increasing treatment exposure.19
Patients who received continuous SC abatacept treatment 
had improvements in disease activity and physical function that 
were maintained over time, supporting the ﬁ  ndings in patients 
with active RA who received SC abatacept with or without 
background MTX.19 Patients who withdrew SC abatacept treat-
ment for 12 weeks experienced increased disease activity and 
slight worsening of physical function. Upon reintroduction, 
improvements in disease activity were noted within 1 month 
of re-initiation and, by the end of period III, disease activity 
was comparable with patients who received continuous SC 
abatacept. Similarly, physical function improved upon reintro-
duction of SC abatacept. These ﬁ  ndings suggest that temporary 
short-term withdrawal of treatment has a minimal impact on 
sustained efﬁ  cacy improvements seen in patients who respond 
to treatment. These are important ﬁ  ndings, and provide some 
conﬁ  dence for clinicians that interruption of SC abatacept treat-
ment for up to 3 months is safe and well tolerated with a limited 
impact on efﬁ  cacy.
Certain limitations of the study design should be considered. 
All patients received background immunosuppressive therapy 
with MTX, and caution should be used when extrapolating these 
conclusions to patients on monotherapy. However, a previous 
study determined that treatment with abatacept alone resulted 
in comparable immunogenicity to abatacept plus MTX, suggest-
ing that the impact of background MTX on immunogenicity with 
SC abatacept is minimal.10 Patients were also permitted rescue 
of treatment was well tolerated without a signiﬁ  cant impact 
on immunogenicity. Following withdrawal of SC abata-
cept, immunogenicity was observed in approximately 10% 
of patients, with only one showing persistent seropositivity. 
The increase in immunogenicity for patients withdrawn from 
treatment was not signiﬁ  cantly different from that of patients 
Figure 3  Clinical efﬁ  cacy. (A) Mean change in DAS28 (CRP) over 
time by period II (Withdrawal phase) treatment group. (B) Proportion 
of patients achieving LDAS and DAS28-deﬁ  ned remission by period II 
(Withdrawal phase) treatment group. (C) Mean change in HAQ-DI score 
over time by period II (Withdrawal phase) treatment group. Data are 
as-observed for all patients who received ≥1 dose of study drug during 
period II. Error bars represent 95% CI. CRP, C reactive protein; DAS28, 
Disease Activity Score 28; HAQ-DI, Health Assessment Questionnaire-
Disability Index; LDAS, low disease activity state; SC, subcutaneous.Clinical and epidemiological research
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therapy with high-dose steroids; however, the number of patients 
who received such rescue therapy is probably too low to inﬂ  uence 
the ﬁ  ndings. Only one 12-week period of withdrawal was evalu-
ated, so the impact of multiple treatment interruptions cannot 
be determined. However, 12 weeks is felt to be a representative 
length of withdrawal in clinical practice and is therefore clinically 
relevant. Furthermore, patients who did not experience any change 
in disease activity (DAS28 reduction <0.6 from baseline to day 78) 
were not randomised to the withdrawal period and entered the 
LTE directly. Such patients could be expected to be at a higher 
risk of immunogenicity, given the link between clinical response 
and immunogenicity seen with some biological agents.8 13 14 20 
In this study a comparable immunogenicity proﬁ  le was seen for 
these patients in the LTE to that seen for patients randomised and 
treated; this will be examined further in a future report.
It should be noted that the analyses presented here are based 
on as-observed data which are vulnerable to drop-outs. However, 
patient retention in this study was high. Lastly, the DAS28 results 
were based on CRP, which may yield higher responses than the 
DAS28 (erythrocyte sedimentation rate); however, CRP has been 
well validated as an outcome measure to assess disease activity21 
and is increasingly used in clinical trials.
In summary, 3-month interruption with subsequent reintro-
duction of SC abatacept was associated with overall low immu-
nogenicity, a ﬁ  nding consistent with that found with intravenous 
abatacept. Furthermore, this stop–start schedule was well toler-
ated and did not have a negative effect on efﬁ  cacy. These ﬁ  ndings 
are important considerations for the clinical use of SC abatacept.
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